Non-Small Cell Lung Cancer Coverage from Every Angle

First-in-Human Study of Lazertinib in EGFR-Mutated Advanced Lung Cancer

By: Kelly M. Hennessey, PhD
Posted: Tuesday, December 10, 2019

In a first-in-human, open-label, multicenter, phase I/II study, Myung-Ju Ahn, MD, of the Sungkyunkwan University School of Medicine in Seoul, Korea, and colleagues reported that the third-generation EGFR tyrosine kinase inhibitor lazertinib had a “tolerable” safety profile and “promising” clinical activity in patients with EGFR-mutated non–small cell lung cancer (NSCLC) that had progressed after EGFR tyrosine kinase inhibitor therapy. The results on dose escalation and dose expansion were published in The Lancet Oncology. A phase II dose-extension study is ongoing.

Prior to the study, all patients had a confirmed diagnosis of locally advanced or metastatic NSCLC and experienced disease progression after previous treatment with first-generation or second-generation EGFR tyrosine kinase inhibitors. In total, 127 patients were evaluable for response. Of those patients, 38 were enrolled into the dose-escalation group, and 89, in the dose-expansion group. The oral doses of this agent tested were 20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 240 mg, or 320 mg once daily continuously in 21-day cycles.

According to an independent central review assessment, 69 patients (54%) had an objective response, including 66 patients (52%) with confirmed partial responses and 3 patients (2%) with confirmed complete responses. Disease control was achieved in 110 patients (87%). No dose-limiting toxicities were observed up to the highest dose tested.

The median duration of response in the overall population was 15.2 months, and the median progression-free survival was 9.5 months. The median progression-free survival was longer in patients with tumors harboring EGFR mutations than in patients with EGFR-negative tumors.

“Lazertinib has a potential therapeutic role in the treatment of NSCLC harboring EGFR mutations, either alone or in combination with other drugs,” the investigators concluded.

Disclosure: Full disclosures of study authors can be found at

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.